One aspect of this differential activity may be influenced by heterogeneous binding partners, such as the findings that GBP1 interacts directly with proto-oncogene serine/threonine kinase 1 (PIM1), a marker of disease progression and treatment resistance in ovarian and other cancers (66, 67). The gene discussed is GBP1; the disease is cancer.